PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26071181-3 2015 Stable overexpression of wild-type CD97 reduced serum starvation- and staurosporine-induced intrinsic and tumor necrosis factor (TNF)/cycloheximide-induced extrinsic apoptosis, indicated by an increase in cell viability, a lower percentage of cells within the subG0/G1 phase, expressing annexin V, or having condensed nuclei, and a reduction of DNA laddering. Staurosporine 70-83 tumor necrosis factor Homo sapiens 106-127 26071181-3 2015 Stable overexpression of wild-type CD97 reduced serum starvation- and staurosporine-induced intrinsic and tumor necrosis factor (TNF)/cycloheximide-induced extrinsic apoptosis, indicated by an increase in cell viability, a lower percentage of cells within the subG0/G1 phase, expressing annexin V, or having condensed nuclei, and a reduction of DNA laddering. Staurosporine 70-83 tumor necrosis factor Homo sapiens 129-132 18281372-8 2008 The in vitro study demonstrated that TNFalpha significantly increased CD40L expression, an effect weakly influenced by aspirin but significantly reduced by AACOCF3, an inhibitor of PLA(2), apocynin, an inhibitor of NADPH oxidase, or staurosporine, an inhibitor of PKC. Staurosporine 233-246 tumor necrosis factor Homo sapiens 37-45 16532035-4 2006 Transforming growth factor alpha protected both species of astrocytes from staurosporine-induced apoptosis. Staurosporine 75-88 tumor necrosis factor Homo sapiens 0-32 16134057-5 2005 To further investigate mRNA expression of TNF, staurosporine was used. Staurosporine 47-60 tumor necrosis factor Homo sapiens 42-45 16134057-10 2005 Staurosporine attenuated mRNA expression of TNF (p < 0.05), but not interleukin (IL)-6, which was detected prior to TNF. Staurosporine 0-13 tumor necrosis factor Homo sapiens 44-47 15096609-6 2004 Thus, it is concluded that an apoptosis-triggering anion conductance is carried by the volume-sensitive outwardly rectifying Cl(-) channel and that the channel activation on apoptotic stimulation with staurosporine, but not with Fas ligand or TNF-alpha, is mediated by ROS. Staurosporine 201-214 tumor necrosis factor Homo sapiens 243-252 14511641-3 2003 During staurosporine-, Fas-, and tumor necrosis factor alpha-induced apoptosis caspase-processed activated CDK11(p46) is generated from larger CDK11(p110) isoforms. Staurosporine 7-20 tumor necrosis factor Homo sapiens 23-60 12707358-2 2003 A protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or a Src kinase inhibitor (PP2) attenuated TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 promoter activity. Staurosporine 36-49 tumor necrosis factor Homo sapiens 152-161 12645577-2 2003 TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ICAM-1 promoter activity was inhibited by a protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or an Src-specific tyrosine kinase inhibitor (PP2). Staurosporine 143-156 tumor necrosis factor Homo sapiens 0-9 11483407-6 2001 PKC inhibitors (staurosporine, Ro 31-8220, calphostin C, or Go 6976) also inhibited TNF-alpha-induced response. Staurosporine 16-29 tumor necrosis factor Homo sapiens 84-93 11369514-5 2001 Staurosporine [protein kinase-C (PK-C) inhibitor] and PD98059 [mitogen-activated protein kinase inhibitor (MAPK)] only partially inhibited GHA-induced TNF-alpha. Staurosporine 0-13 tumor necrosis factor Homo sapiens 151-160 11078718-6 2000 Staurosporine and the PKC-delta inhibitor rottlerin inhibited TNF-alpha-triggered serine but not threonine phosphorylation. Staurosporine 0-13 tumor necrosis factor Homo sapiens 62-71 10946303-5 2000 The PKC inhibitor, staurosporine, also inhibited TNF-alpha-induced response. Staurosporine 19-32 tumor necrosis factor Homo sapiens 49-58 10946303-7 2000 NF-kappaB DNA-protein binding and COX-2 promoter activity were enhanced by TNF-alpha, and these effects were inhibited by genistein, U73122, staurosporine, or pyrolidine dithiocarbamate. Staurosporine 141-154 tumor necrosis factor Homo sapiens 75-84 10903772-7 2000 PMA and TNF-alpha stimulation of GM-CSF required activation of PKC (inhibition by staurosporine and bisindolylmaleimide I). Staurosporine 82-95 tumor necrosis factor Homo sapiens 8-17 10542243-1 1999 Expression of the pleiotropic cytokine interleukin (IL)-6 can be stimulated by the proinflammatory cytokine tumor necrosis factor (TNF) and the microbial alkaloid staurosporine (STS). Staurosporine 178-181 tumor necrosis factor Homo sapiens 131-134 10477396-8 1999 TNF-alpha decreased VEGF production; the effect of TNF-alpha was neutralized by 10 nM staurosporine. Staurosporine 86-99 tumor necrosis factor Homo sapiens 0-9 10477396-8 1999 TNF-alpha decreased VEGF production; the effect of TNF-alpha was neutralized by 10 nM staurosporine. Staurosporine 86-99 tumor necrosis factor Homo sapiens 51-60 10448011-3 1999 Treatment of PMN with genistein, staurosporine, and wortmannin, inhibitors of tyrosine kinases, protein kinase C, and phosphotidylinostol 3-kinase (PI 3-kinase) respectively, completely blocked the TNF-stimulated respiratory burst in PMN. Staurosporine 33-46 tumor necrosis factor Homo sapiens 198-201 10408834-7 1999 Both the FMLP- and the TNF-alpha-dependent systems were also found to be equally susceptible to inhibition by various inhibitors of kinases (genistein, staurosporin, 1-(5-isoquinolinnylsulphonyl)-2-methylpiperazine and wortmannin). Staurosporine 152-164 tumor necrosis factor Homo sapiens 23-32 9754656-8 1998 Further, the differentiation of p55 transfectants induced by TNF was reduced by the inhibitor of protein-kinase-C (PKC), staurosporine. Staurosporine 121-134 tumor necrosis factor Homo sapiens 61-64 9533826-6 1998 Phorbol esters (PMA), activators of PKC, also raised the immunoreactive levels of ET-1 and Big ET-1 while, staurosporine, a PKC inhibitor (20 nm), decreased ET-1 levels in TNF-alpha-stimulated cells. Staurosporine 107-120 tumor necrosis factor Homo sapiens 172-181 9395855-2 1997 Staurosporine (STS) reportedly potentiates TNF-mediated cytotoxicity in cancer cell lines via inhibition of PKC. Staurosporine 0-13 tumor necrosis factor Homo sapiens 43-46 9395855-2 1997 Staurosporine (STS) reportedly potentiates TNF-mediated cytotoxicity in cancer cell lines via inhibition of PKC. Staurosporine 15-18 tumor necrosis factor Homo sapiens 43-46 9395784-9 1997 Tumour necrosis factor alpha (TNF-alpha)-induced membrane expression of PR-3 could be blocked with the RNA synthesis inhibitor actinomycin D, the protein kinase C (PKC) and proteinase A (PKA) inhibitor staurosporine, the specific PKA inhibitor calphostin C, the c-AMP-dependent PKA inhibitor KT5720 and the tyrosine kinase inhibitor genistein in a dose-dependent manner. Staurosporine 202-215 tumor necrosis factor Homo sapiens 30-39 9568551-5 1997 Additionally, staurosporine (to LPS and PMA) and HBA (to LPS only) inhibited the activation of these mitogen-activated protein kinase (MAPK) isoforms at doses 10-100 fold higher than those required to inhibit maximal TNF alpha production. Staurosporine 14-27 tumor necrosis factor Homo sapiens 217-226 9178968-9 1997 In contrast, LPS-stimulated TNF-alpha secretion was markedly inhibited by not only herbimycin A or genistein, but also staurosporin. Staurosporine 119-131 tumor necrosis factor Homo sapiens 28-37 9023325-7 1997 In contrast, TNF-alpha production in response to okadaic acid was inhibited by the TNF-converting enzyme inhibitor GI 129471 and staurosporin but was unaffected by either IL-1ra, dexamethasone or NS-398. Staurosporine 129-141 tumor necrosis factor Homo sapiens 13-22 9003773-3 1996 Here we show that the C-terminal 42 amino acid peptide of the retinoblastoma (Rb) protein, an important cell cycle regulator with a known anti-apoptotic function, is specifically cleaved off by an ICE-like protease in tumour necrosis factor (TNF)- and staurosporine-induced apoptosis. Staurosporine 252-265 tumor necrosis factor Homo sapiens 218-240 9003773-3 1996 Here we show that the C-terminal 42 amino acid peptide of the retinoblastoma (Rb) protein, an important cell cycle regulator with a known anti-apoptotic function, is specifically cleaved off by an ICE-like protease in tumour necrosis factor (TNF)- and staurosporine-induced apoptosis. Staurosporine 252-265 tumor necrosis factor Homo sapiens 242-245 8980909-5 1996 The PKC inhibitors (H7, calphostin C, and staurosporine) inhibited TNF-induced uPA expression and secretion in a dose-dependent manner. Staurosporine 42-55 tumor necrosis factor Homo sapiens 67-70 8627883-12 1996 To further confirm our findings that PKC may regulate endogenous TNF expression, a PKC inhibitor, staurosporine, was used. Staurosporine 98-111 tumor necrosis factor Homo sapiens 65-68 8627883-17 1996 After factoring out the cytotoxicity of staurosporine, the TNF-mediated cytotoxicity increased to 39.3% and 28.7% for the SK-RC-42 and SK-RC-49 cells, respectively. Staurosporine 40-53 tumor necrosis factor Homo sapiens 59-62 8611631-6 1996 Treatment with TNF-alpha for 4-24 h increased the cPLA2 protein and mRNA levels which were blocked by the broad inhibitor of protein kinases staurosporine, the protein kinase C (PKC) inhibitor calphostin C, and to a lesser extent the calcium/calmodulin-dependent protein kinase inhibitor W-7. Staurosporine 141-154 tumor necrosis factor Homo sapiens 15-24 8580367-1 1995 The protein kinase C (PKC) inhibitors bisindolylmaleimide, calphostin C, H-7 and staurosporine were examined for their effect on tumour necrosis factor (TNF) cytotoxic activity. Staurosporine 81-94 tumor necrosis factor Homo sapiens 129-151 8580367-1 1995 The protein kinase C (PKC) inhibitors bisindolylmaleimide, calphostin C, H-7 and staurosporine were examined for their effect on tumour necrosis factor (TNF) cytotoxic activity. Staurosporine 81-94 tumor necrosis factor Homo sapiens 153-156 7750120-6 1995 Staurosporine (2-50 nM), which has been reported to augment the effects of TNF alpha, was less effective than tamoxifen against WITG3 and, in addition, was markedly inhibitory to non-neoplastic glial cells. Staurosporine 0-13 tumor necrosis factor Homo sapiens 75-84 8089485-10 1994 Staurosporine greatly enhanced the sensitivity of U-937 cells to the cytotoxic effect of TNF. Staurosporine 0-13 tumor necrosis factor Homo sapiens 89-92 8000707-7 1994 TNF alpha-induced responses were completely inhibited by cytochalasin B and staurosporin, and partially blocked by pertussis toxin. Staurosporine 76-88 tumor necrosis factor Homo sapiens 0-9 8022202-0 1994 Redox reagents and staurosporine inhibit stimulation of the transcription regulator NF-kappa B following tumour necrosis factor treatment of chronic B-leukaemia cells. Staurosporine 19-32 tumor necrosis factor Homo sapiens 105-127 8022202-10 1994 However, the protein kinase inhibitor staurosporine inhibited TNF induction of NF-kappa B in four of five samples, suggesting that staurosporine-sensitive protein kinases (other than PKC) are involved in the signalling pathway. Staurosporine 38-51 tumor necrosis factor Homo sapiens 62-65 8204888-9 1994 The PKC inhibitor staurosporine at low concentrations (100 ng/mL) caused a significant augmentation of MMP-9 release in untreated cultures that was blocked by the addition of anti-TNF-alpha. Staurosporine 18-31 tumor necrosis factor Homo sapiens 180-189 8144608-0 1994 Staurosporine induces the cell surface expression of both forms of human tumor necrosis factor receptors on myeloid and epithelial cells and modulates ligand-induced cellular response. Staurosporine 0-13 tumor necrosis factor Homo sapiens 73-94 8144608-2 1994 In this report, we examined the effect of staurosporine on the constitutive expression of tumor necrosis factor (TNF) receptors in K562, a human erythroblastoid leukemic cell line. Staurosporine 42-55 tumor necrosis factor Homo sapiens 90-111 8144608-2 1994 In this report, we examined the effect of staurosporine on the constitutive expression of tumor necrosis factor (TNF) receptors in K562, a human erythroblastoid leukemic cell line. Staurosporine 42-55 tumor necrosis factor Homo sapiens 113-116 8144608-3 1994 Exposure of these cells to staurosporine enhanced cell surface expression of TNF receptors by almost 7-fold in a dose- and time-dependent fashion. Staurosporine 27-40 tumor necrosis factor Homo sapiens 77-80 8144608-7 1994 TNF receptors were induced by staurosporine on a wide variety of human cells of both epithelial (primarily p60 receptors) and myeloid (mainly p80 receptor) origin. Staurosporine 30-43 tumor necrosis factor Homo sapiens 0-3 8144608-10 1994 Furthermore, we found that staurosporine had no effect on the internalization or shedding of the receptor, but it induced the mRNA for both forms of the TNF receptor. Staurosporine 27-40 tumor necrosis factor Homo sapiens 153-156 8144608-12 1994 Modulation of the receptor number by staurosporine correlated with the enhancement of antiproliferative effects of TNF against different tumor cells. Staurosporine 37-50 tumor necrosis factor Homo sapiens 115-118 7905502-6 1994 The protein kinase C inhibitors staurosporin and calphostin C inhibited both the TNF-, PMA-, and adherence-induced release of soluble forms of TNFRs. Staurosporine 32-44 tumor necrosis factor Homo sapiens 81-84 8276122-7 1994 The effect of IFNs on the TNF receptors was inhibited by staurosporin, a protein kinase C (PK-C) inhibitor. Staurosporine 57-69 tumor necrosis factor Homo sapiens 26-29 8258685-5 1993 Protein kinase C inhibition by staurosporine reduced LPS induction of TNF-alpha, whereas it had no effects on IL-6 and IL-1 beta. Staurosporine 31-44 tumor necrosis factor Homo sapiens 70-79 7504465-2 1993 TNF induced metalloproteinase transcription could be inhibited with either protein kinase inhibitors (H7 or staurosporine) or by raising intracellular cAMP levels. Staurosporine 108-121 tumor necrosis factor Homo sapiens 0-3 8325335-6 1993 TNF-alpha secretion in response to both Nocardia fractions was inhibited by sphingosine, staurosporine and calphostin C, known PKC inhibitors, as well as by a PKC depletion procedure. Staurosporine 89-102 tumor necrosis factor Homo sapiens 0-9 8391810-2 1993 Evidence is also presented that staurosporine not only did not inhibit, but amplified the potentiation of phagocytosis by PMA and TNF-alpha. Staurosporine 32-45 tumor necrosis factor Homo sapiens 130-139 7683925-3 1993 The PKC inhibitors (H-7, staurosporine, and calphostin C), but not HA-1004, inhibited TNF-induced uPA expression, synthesis, and secretion in a dose-dependent manner. Staurosporine 25-38 tumor necrosis factor Homo sapiens 86-89 7681061-7 1993 This hypothesis was confirmed by experiments with the PKC inhibitors staurosporine and calphostin C, which prevented the induction of IL-1 mRNA by TNF and accelerated the decay of this mRNA in cells pretreated with TNF. Staurosporine 69-82 tumor necrosis factor Homo sapiens 147-150 7681061-7 1993 This hypothesis was confirmed by experiments with the PKC inhibitors staurosporine and calphostin C, which prevented the induction of IL-1 mRNA by TNF and accelerated the decay of this mRNA in cells pretreated with TNF. Staurosporine 69-82 tumor necrosis factor Homo sapiens 215-218 8490103-6 1993 The IC50 values for the inhibition of TNF alpha production were 0.2 nM for staurosporine, and 20 nM for K252a, Calphostin C and chelerythrine. Staurosporine 75-88 tumor necrosis factor Homo sapiens 38-47 7678355-7 1993 The TNF-alpha- and PMA-stimulated VCAM-1 expression is inhibited by the PKC and PKA inhibitor staurosporine (STS). Staurosporine 94-107 tumor necrosis factor Homo sapiens 4-13 7678355-7 1993 The TNF-alpha- and PMA-stimulated VCAM-1 expression is inhibited by the PKC and PKA inhibitor staurosporine (STS). Staurosporine 109-112 tumor necrosis factor Homo sapiens 4-13 1429672-8 1992 Protein kinase C inhibitors, such as H7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine), staurosporine, and sphingosine, reduce TNF alpha secretion stimulated by PMA. Staurosporine 90-103 tumor necrosis factor Homo sapiens 129-138 1327540-4 1992 To investigate the intracellular pathway involved in the TNF-mediated activation of mycobacteriostatic/mycobactericidal activity in macrophages, we used two different protein kinase C (PKC) inhibitors: H7 (10(-5)-10(7) M) and staurosporine (10(-7)-10(-9) M). Staurosporine 226-239 tumor necrosis factor Homo sapiens 57-60 1639861-4 1992 Two PKC inhibitors, H7 and staurosporine (SS), abrogated IL-1 beta induced TNF-alpha expression in a dose-dependent fashion. Staurosporine 27-40 tumor necrosis factor Homo sapiens 75-84 1639861-4 1992 Two PKC inhibitors, H7 and staurosporine (SS), abrogated IL-1 beta induced TNF-alpha expression in a dose-dependent fashion. Staurosporine 42-44 tumor necrosis factor Homo sapiens 75-84 1730737-4 1992 Thus, induction of NF-kappa B and p51 mRNA by TNF-alpha was not mediated by a staurosporin-sensitive factor, but NF-kappa B activation by TNF-alpha was even reduced by action of a staurosporin-sensitive factor. Staurosporine 180-192 tumor necrosis factor Homo sapiens 46-55 1730737-4 1992 Thus, induction of NF-kappa B and p51 mRNA by TNF-alpha was not mediated by a staurosporin-sensitive factor, but NF-kappa B activation by TNF-alpha was even reduced by action of a staurosporin-sensitive factor. Staurosporine 180-192 tumor necrosis factor Homo sapiens 138-147 1730737-5 1992 Decreased levels of phosphorylation of TNF-R alpha (TNF receptor type alpha) after staurosporin-treatment correlated with increased induction of NF-kappa B by TNF-alpha. Staurosporine 83-95 tumor necrosis factor Homo sapiens 159-168 1707932-6 1991 At 24 h, staurosporine itself induces intercellular adhesion molecule 1 and class I MHC, and acts additively with TNF. Staurosporine 9-22 tumor necrosis factor Homo sapiens 114-117 2386936-1 1990 We have examined the effect of the protein kinase C (PKC) inhibitor, staurosporine, on tumor necrosis factor (TNF)-induced cytotoxic action and augmentation of human immunodeficiency virus (HIV) expression on the chronically HIV-infected T-cell line, MOLT-4/HIV (HTLV-IIIB strain). Staurosporine 69-82 tumor necrosis factor Homo sapiens 110-113 2386936-2 1990 Staurosporine enhanced the decrease in the number of viable cells caused by TNF treatment for 3 days (1 ng/ml of TNF, 43% decrease; 1 ng/ml of TNF + 20 nM staurosporine, 94%), whereas the cytotoxic action on that cell line induced by 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA), which was known to be an activator of PKC, was partially inhibited by staurosporine. Staurosporine 0-13 tumor necrosis factor Homo sapiens 76-79 2386936-2 1990 Staurosporine enhanced the decrease in the number of viable cells caused by TNF treatment for 3 days (1 ng/ml of TNF, 43% decrease; 1 ng/ml of TNF + 20 nM staurosporine, 94%), whereas the cytotoxic action on that cell line induced by 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA), which was known to be an activator of PKC, was partially inhibited by staurosporine. Staurosporine 0-13 tumor necrosis factor Homo sapiens 113-116 2386936-2 1990 Staurosporine enhanced the decrease in the number of viable cells caused by TNF treatment for 3 days (1 ng/ml of TNF, 43% decrease; 1 ng/ml of TNF + 20 nM staurosporine, 94%), whereas the cytotoxic action on that cell line induced by 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA), which was known to be an activator of PKC, was partially inhibited by staurosporine. Staurosporine 0-13 tumor necrosis factor Homo sapiens 113-116 2386936-2 1990 Staurosporine enhanced the decrease in the number of viable cells caused by TNF treatment for 3 days (1 ng/ml of TNF, 43% decrease; 1 ng/ml of TNF + 20 nM staurosporine, 94%), whereas the cytotoxic action on that cell line induced by 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA), which was known to be an activator of PKC, was partially inhibited by staurosporine. Staurosporine 155-168 tumor necrosis factor Homo sapiens 76-79 2386936-2 1990 Staurosporine enhanced the decrease in the number of viable cells caused by TNF treatment for 3 days (1 ng/ml of TNF, 43% decrease; 1 ng/ml of TNF + 20 nM staurosporine, 94%), whereas the cytotoxic action on that cell line induced by 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA), which was known to be an activator of PKC, was partially inhibited by staurosporine. Staurosporine 360-373 tumor necrosis factor Homo sapiens 76-79 2386936-3 1990 In addition, staurosporine augmented the TNF cytotoxic activity against other cell lines including HIV-uninfected U937 cells(100 ng/ml of TNF, 53% decrease in the number of viable cells; 100 ng/ml of TNF + 5 nM staurosporine, 86%). Staurosporine 13-26 tumor necrosis factor Homo sapiens 41-44 2386936-3 1990 In addition, staurosporine augmented the TNF cytotoxic activity against other cell lines including HIV-uninfected U937 cells(100 ng/ml of TNF, 53% decrease in the number of viable cells; 100 ng/ml of TNF + 5 nM staurosporine, 86%). Staurosporine 13-26 tumor necrosis factor Homo sapiens 138-141 2386936-3 1990 In addition, staurosporine augmented the TNF cytotoxic activity against other cell lines including HIV-uninfected U937 cells(100 ng/ml of TNF, 53% decrease in the number of viable cells; 100 ng/ml of TNF + 5 nM staurosporine, 86%). Staurosporine 13-26 tumor necrosis factor Homo sapiens 138-141 2386936-7 1990 These results suggest that TPA and TNF facilitate HIV replication by different pathways and that staurosporine augments TNF cytotoxicity by possible suppression of PKC activity in both HIV-infected and uninfected cells. Staurosporine 97-110 tumor necrosis factor Homo sapiens 120-123 2167234-3 1990 In addition, 100-200 nM staurosporine, a more potent inhibitor of protein kinase C, also completely suppressed GM-CSA from IL-1 beta- and TNF alpha-induced fibroblasts. Staurosporine 24-37 tumor necrosis factor Homo sapiens 138-147 2117917-5 1990 The increased PGE production provoked by tumour necrosis factor alpha (TNF alpha) in RSC was also augmented by staurosporine, but, in contrast, the increases in cellular [Fru(2,6)P2] induced by transforming growth factor beta (TGF beta) and interferon-gamma (IFN-gamma) were diminished. Staurosporine 111-124 tumor necrosis factor Homo sapiens 71-80 2117917-7 1990 These findings suggest that IL-1 alpha and probably TNF alpha act via an intracellular mechanism different from that mediating the action of TPA, TGF-beta and IFN-gamma, and provide evidence that staurosporine is capable of amplifying the IL-1 signal. Staurosporine 196-209 tumor necrosis factor Homo sapiens 52-61 2186042-5 1990 Preincubation of Jurkat cells with protein kinase inhibitor H7 or staurosporine blocked PK-C activation by either TNF or phorbol 12-myristate 12-acetate (PMA). Staurosporine 66-79 tumor necrosis factor Homo sapiens 114-117 2324095-4 1990 In addition, induction of PAI-2 synthesis by TNF was blocked by two PKC inhibitors, staurosporine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride. Staurosporine 84-97 tumor necrosis factor Homo sapiens 45-48 2324095-6 1990 Staurosporine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride also inhibited both TNF- and phorbol myristate acetate-induced PAI-2 mRNA accumulation. Staurosporine 0-13 tumor necrosis factor Homo sapiens 100-103 2297791-6 1990 Staurosporine, a potent inhibitor of PKC in vitro, inhibited Tac expression marginally in YT cells stimulated with FK, and enhanced Tac expression in cultures treated with TPA, TNF alpha, or IL-1. Staurosporine 0-13 tumor necrosis factor Homo sapiens 177-186